Navigation Links
Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
Date:9/25/2007

LOD, Israel, Sept. 25 /PRNewswire/ -- Glycominds Ltd., a biodiagnostics company specializing in glycan biomarkers for diagnosis and disease management of autoimmune diseases and cancer, announced today that has entered the Biomolecular Photonic (BMP) Consortium. BMP is a new consortium funded by the Government of Israel to improve in-vivo imaging diagnostics for Crohn's disease (CD) and colorectal cancer. The BMP consortium was approved for three years and was granted $4 million for its first year.

"We are very pleased to join the BMP consortium," stated Dr. Nir Dotan, Glycominds' co-founder, CTO and VP, R&D. "Combining biomarker experience with our glycan technology will promote the in-vivo imaging technology developed in Israel. Our collaboration with companies such as Given Imaging (Nasdaq: GIVN) will accelerate the new concept of combining in vitro-in vivo assays towards sensitive biomolecular imaging techniques to enable a more rapid, accurate and earlier diagnosis of Crohn's disease and colorectal cancer."

"Glycominds' glycan biomarker technology stands out as innovative and unique, providing the consortium with proven biomarkers for Crohn's disease and a great opportunity for diagnosing colorectal cancer," stated Dr. Elisha Rabinovitz, the head of the Israeli consortium and Given Imaging CSO. "I believe that glycan technology has the potential to enhance CD diagnosis and early detection of cancers. Glycominds is clearly pioneering the implementation of glycan biomarkers."

About Glycominds Ltd.

Glycominds Ltd. is a biodiagnostics company specialized in developing and commercializing glycan biomarkers, a new class of early diagnostic and prognostic tests based on complex sugar molecules for the detection and management of autoimmune diseases and cancer. The company's goal is to provide physicians with tools that improve treatment selection in autoimmune diseases and early detection of cancers.

Glycominds lead product, IBDX(R), a blood test for early diagnosis of Inflammatory Bowel Disease (IBD) and the prognosis of Crohn's disease severity is commercialized in Israel and Europe, with a U.S. launch planned in early 2008. The Company's gMS(TM) Dx, a blood test for early diagnosis of Multiple Sclerosis (MS), and gMS(TM) PRO, a prognostic test for MS activity, are also expected to enter the market in 2008. Other pipeline products of Glycominds' include blood tests for the prediction of recurrent pregnancy losscaused by antiphoshpholipids syndrome (APS), and first-in-class screening tests for breast and colorectal cancers.

For more information, please contact:

Glycominds, Ltd.

Dr. Avinoam Dukler

Chief Executive Officer

dukler@glycominds.com

The Ruth Group

Sara Ephraim (investors)

Phone: 646-536-7002

sephraim@theruthgroup.com

Janine McCargo (media)

Phone: 646-536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Glycominds Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Chemical-petroleum executive joins Virent Energy board
2. Schneider National exec joins TrafficCast board
3. Doyle joins governors in support of stem cell bill
4. Genomics researcher Hood joins NimbleGen board
5. Fergus joins Baird Venture Partners, Caden Bio
6. Meier joins Broadlook Technologies as COO
7. Prodesse joins forces with Invitrogen
8. Wisconsin joins price-fixing suit vs. D-RAM makers
9. Napier joins board of Third Wave Technologies
10. Schmidt rejoins Renaissance Learning
11. Tommy Thompson joins drug company as advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 Infectex Ltd., a Russian portfolio ... 2b-3 clinical study of SQ109 added to the standard drug therapy regimen in patients ... scientists at Sequella, Inc. ( USA ) and the US National Institutes ... ... Maxwell Biotech Venture Fund Logo ...
(Date:3/27/2017)... The new research portal will give ... reports on Valero Energy , offering extensive market research ... ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) The latest trend gaining ... Ethanol today, even though touted as a green alternative to ...
(Date:3/27/2017)... DIEGO , March 27, 2017  Trovagene, Inc. ... that its Chief Executive Officer, Bill Welch , ... April 4, 2017 at 9:00 AM EDT at the ... .  Bill Welch, and Chief Scientific Officer, Mark ... with investors during the conference.   The presentation ...
(Date:3/24/2017)... Ga. , March 24, 2017 MiMedx ... biopharmaceutical company utilizing human placental tissue allografts and patent-protected ... for multiple sectors of healthcare, announced today  that it ... New York , NY.  Parker H. "Pete" ... Chief Financial Officer, Christopher M. Cashman , EVP ...
Breaking Biology Technology:
(Date:2/27/2017)... Feb. 27, 2017   Strategic Cyber Ventures , ... has led a $3.5 million investment in  Polarity , ... Cyber Ventures is DC based and is led by ... Thomas . Ron Gula , also a longtime ... participated in this series A round of funding. This ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader ... its elite iris biometric solution on the latest ... LTE at Mobile World Congress 2017 (February ... Booth in Hall 3, Stand 3E10. ... Qualcomm Haven™ security platform—a combination of hardware, ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
Breaking Biology News(10 mins):